Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics reported that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.
Subscribe to our email newsletter
Seattle Genetics entered into this collaboration with Millennium in April 2009, at which time Millennium has obtained an exclusive ADC license to an initial antigen expressed on solid tumors as well as two options for exclusive licenses to additional targets.
Under the terms of the ADC collaboration, Millennium is responsible for research, product development, manufacturing and commercialization of any ADC products resulting from the collaboration.
In addition to the companies’ ADC technology collaboration, Seattle Genetics and Millennium are jointly developing brentuximab vedotin, an ADC directed to CD30.
Seattle Genetics submitted a Biologics License Application to the US Food and Drug Administration for brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma in February 2011.
Under the terms of the collaboration agreement, Seattle Genetics has US and Canadian commercialization rights and Takeda has rights to commercialize brentuximab vedotin in the rest of the world.